<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02709720</url>
  </required_header>
  <id_info>
    <org_study_id>GECP 15/02_NORA</org_study_id>
    <nct_id>NCT02709720</nct_id>
  </id_info>
  <brief_title>Locally Advanced Trial of Tri-weekly Metronomic Oral Vinorelbine and Cisplatin as Induction Therapy and Subsequent Concomitance With Radiation Therapy in Patients With Unresectable Non Small Cell Lung Cancer (NSCLC)</brief_title>
  <acronym>NORA</acronym>
  <official_title>Phase II Clinical Trial With Metronomic Oral Vinorelbine and Tri-weekly Cisplatin as Induction Therapy and Subsequent Concomitantly With Radiotherapy (RT) in Patients With Lung Cancer (NSCLC) Locally Advanced Unresectable</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Lung Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Lung Cancer Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as
      induction therapy and subsequent concomitantly with radiotherapy (RT) in patients with lung
      cancer (NSCLC) locally advanced unresectable
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: At present, administration of concomitant chemotherapy and radiation therapy is
      considered a treatment of choice for patients with unresectable stage III tumor selected
      clinically.

      There is at present a systemic considered standard treatment in combination with radical
      radiotherapy. Nor is it established a dose of standard radiation therapy, but it is known
      that should never be less than 60Gy57.

      Vinorelbine has shown a strong radio-sensitizer in-vitro37 effect. In the phase II study, The
      combination of oral vinorelbine with cisplatin as induction therapy and then concomitantly
      with radiotherapy (66Gy) has provided very encouraging efficacy results. Recently in the
      vortex scheme cisplatin study with oral vinorelbine concomitant maintained with radiation
      from the second cycle of chemotherapy was tested.

      It is therefore a priority in this segment pathology seeking treatment regimens that improve
      the effectiveness and toxicity. Metronomic chemotherapy started with the idea of
      administering a cytostatic divided doses, for an extended period without interruption, can
      provide the advantage of exposing patients to significant dose chemotherapy without worsening
      the toxicity profile. All this makes it an attractive treatment strategy, and can also
      maintain radio sensitizing effect during concomitance.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 15, 2016</start_date>
  <completion_date type="Anticipated">April 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy (according to progression-free survival of patient)</measure>
    <time_frame>From patient inclusion up to the date of first documented progression or date of death from any cause, whichever came first, up to 12 months.</time_frame>
    <description>To evaluate the efficacy in terms of progression-free survival (PFS) of oral metronomical vinorelbine and cisplatin as an induction treatment and then with concomitant radiotherapy. The PFS is defined as the time from the moment of patient inclusion to the documentation of progression or death from any cause (patients who die without evidence of progression, will be considered events on the date of death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Measured during the first assessment of the patient, up to 6 weeks from the inclusion of the patient</time_frame>
    <description>The objective response rate will be calculated from the sum of the number of patients whose best response is complete response and partial response divided by the total number of patients eligible for the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From inclusion in the study to death (estimated period 12 months)</time_frame>
    <description>Overall survival will be measured from the date of patient inclusion until death or loss of follow-up. In patients who have not died, the duration of survival will be censored on the date of the last contact if the patient causes loss of follow-up or on the date of the latest news.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by common toxicity criteria (CTCAE) v4.0</measure>
    <time_frame>From first drug administration to 30 days after last administration and 90 days after radiotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 cycles of metronomic Vinorelbine 50 mg + cisplatin, followed by 2 cycles of Vinorelbine 30 mg + cisplatin concomitant with radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cycle 1 and 2 day 1, 80 mg/m2</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cycle 3 and 4 day 1, 80 mg/m2</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>concomitant therapy during cycles 3 and 4. Total dose: 66Gy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with histologically confirmed recent non small cell lung cancer unresectable
             stage IIIA and IIIB.

          -  Perform a baseline positron emission tomography (PET-CT) to rule out the presence of
             distant disease and confirm that it is a non-NSCLC radical surgical treatment
             candidate.

          -  The positive mediastinal lymph nodes by PET-CT must be confirmed histologically.
             Mediastinal involvement may be considered without histologically observe when there is
             a mass of lymph nodes where the margins are not distinguished.

          -  At least one measurable lesion on computerized tomography (CT).

          -  Performance status 0-1.

          -  Life expectancy&gt; 12 weeks.

          -  Age ≥18 years and ≤ 75 years.

          -  Right renal function: creatinine ≤ 1.5 mg / dl or creatinine clearance&gt; 60 ml / min.

          -  Right hematologic function: hemoglobin&gt; 10 g / dl, neutrophils ≥ 1500 / mm3 and
             platelets ≥ 100,000 / mm3.

          -  Right hepatic function: bilirubin ≤ 1.5 times the upper limit of each center,
             transaminases ≤ 2.5 above the normal limit.

          -  Right lung function without bronchodilators: defined by a forced expiratory volume in
             1 second (FEV1)&gt; 50% of predicted normal volume and lung diffusing capacity for carbon
             monoxide (DLCO)&gt; 40% of predicted normal.

          -  The proportion of normal lung exposed to&gt; 20 Gy RT (V20) shall be ≤ 35%.

          -  Signature of informed consent.

        Exclusion Criteria:

          -  Weight loss&gt; 10% in the 3 months prior to study entry.

          -  Intestinal problems that do not ensure proper absorption of oral vinorelbine.

          -  Pregnant or lactating women. Women of childbearing potential should have a negative
             pregnancy test, and both men and women under this condition should take contraceptive
             measures throughout the study.

          -  symptomatic sensory neuropathy&gt; grade 1 toxicity criteria according to the CTCAE v4.

          -  Comorbidities uncontrolled.

          -  syndrome of the superior vena cava.

          -  pleural or pericardial effusion: are both considered as indicative of metastatic
             disease unless proven otherwise. Those who still remain cytologically negative for
             malignancy, are exudates also be excluded. It may include those with pleural effusion
             visible on chest radiography or too small to perform diagnostic puncture safely.

          -  Known hypersensitivity to drugs with similar study drug structure.

          -  Previous treatment with anticancer drugs, previous surgery or thoracic radiotherapy
             for lung cancer or for other reasons.

          -  History of other malignancy treated properly within 5 years except carcinoma in situ
             of the cervix or breast skin and basal cell carcinoma.

          -  Concomitant treatment with other antineoplastic drug or investigational.

          -  Patients at any psychological, family, sociological or geographical that may hinder
             compliance with the study protocol and monitoring program.

          -  history of neurological or psychiatric disorders that impede a properly understanding
             of the informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariano Provencio, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Puerta de Hierro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bartomeu Massutí, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario de Alicante</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa Morán, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Luis González Larriba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico San Carlos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Dómine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Jiménez Díaz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Miguel Sánchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de la Princesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramón de las Peñas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Provincial de Castellón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María Guirado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Gnral de Elche</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dolores Isla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Lozano Blesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raquel Marsé, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Son Espases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª Angeles Sala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Basurto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Coves, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Son Llátzer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Laura Ortega, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Jaén</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Vicente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen Macarena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Regina Gironés, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital LLuís Alcanyís</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Paredes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Donostia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margarita Majem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Sant Pau i de la Santa Creu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio Vázquez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Lucus Agustí</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO-Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Castellón</name>
      <address>
        <city>Castelló de la Plana</city>
        <state>Castelló</state>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lluís Alcanyís</name>
      <address>
        <city>Xàtiva</city>
        <state>Valencia</state>
        <zip>46800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.G.U. Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Son Llàtzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. de Donostia</name>
      <address>
        <city>San Sebastian</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de La Macrena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.gecp.org</url>
    <description>Spanish Lung Cancer Group website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2016</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>Cancer Lung Disease</keyword>
  <keyword>NORA</keyword>
  <keyword>GECP 15/02</keyword>
  <keyword>Metronomic administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

